Bloomlife MFM-Pro uses cloud-based processing to algorithmically extract maternal and fetal heart rates. Credit: Gorodenkoff/shutterstock.com.

Maternal health company Bloomlife has announced the US Food and Drug Administration (FDA) clearance of its Bloomlife MFM-Pro device.

The Bloomlife MFM-Pro prescription-based wearable device is designed to monitor maternal and fetal heart rates, facilitating care in both home and clinical settings.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It can non-invasively measure the body’s electrical activity and uses cloud-based processing to algorithmically extract maternal and fetal heart rates.

Bloomlife co-founder and CEO Eric Dy said: “Our pioneering consumer pregnancy tracker proved that women want access to more information during a pivotal time of their life. The FDA clearance of Bloomlife MFM-Pro marks an important milestone by cementing our transition from consumer to medical markets.”

The latest approval follows Bloomlife’s partnership with Perigen to improve access to essential high-risk pregnancy monitoring.

The partnership, which was announced earlier this month, will combine remote patient monitoring and AI-driven analytics to bring cost-effective procedures to patients.

Bloomlife said it aims to leverage technology to shift care from high-cost clinical environments to the home, aiming to provide evidence-based, cost-effective, high-quality, patient-centered care.

Dy added: “Covid revealed a significant amount of maternal care can be done outside of clinical settings. However, there remains a need to augment basic telehealth appointments with objective physiological data.

“Utilisation of connected care solutions can not only increase the quality of virtual appointments, but allow us to build a more efficient, equitable, and scalable means of screening and managing the health of mom and baby.”

Bloomlife designs solutions for remote maternal health to improve the health and well-being of mothers and babies.